J. Cabezas

PROPARGYLATION OF CARBONYL COMPOUNDS : AN EFFICIENT METHOD FOR THE SYNTHESIS OF HOMOPROPARGYL ALCOHOLS

Abstract Controlled dilithiation of allene, with two equivalents of n-butyllithium, produces the propargyl dianion 5 . The latter couples efficiently with carbonyl compounds to produce homopropargyl alcohols in high yields.

A new method for the preparation of 1,3-dilithiopropyne: an efficient synthesis of homopropargyl alcohols ☆

Abstract Controlled dilithiation of propargyl bromide with two equivalents of n -butyllithium, in the presence of TMEDA, produces the operational equivalent of the dianion 1,3-dilithiopropyne. The latter reacts efficiently with aldehydes and ketones to produce homopropargyl alcohols in a single step route and in high yields.

Effectiveness of ribavirin use associated with direct-acting antivirals in the treatment of non-cirrhotic patients with genotype 1a or 4 HCV infection in real-world practice

effectiveness. Methods: Retrospective, multicentric national study that included patients treated according to clinical practice in Spain. Data were collected from the HEPA-C National Registry (AEEH-CIBERehd). The study evaluated data from patients with genotype 1 or 4 treated in 41 Spanish centers, from1April to 30October 2016. Theprimaryendpoint for effectiveness was sustained viral response at week 12 (SVR12). Results: A total of 3,412 patients were included in the study, 56.4% males, mean age of 58 years, most of the genotype 1b (68.8%) (genotype 1a:22%; genotype 4:7%). Patient distribution according to the degree of fibrosis: F4 (52%), F3 (18%), F2 (19%) and F0–1 (9%). 27.2% of patients received LDV/SOF, 27.4% LDV/SOF + RBV, 24.8% OBV/ PTV/rtv/DSV + RBV, 17.5% OBV/PTV/rtv/DSV and 2.6% OBV/PTV + RBV. 54.8% received RBV. Regarding treatment duration, 82.9% of patients received 12 weeks of treatment, 14.3% 24 weeks and 2.8% 8 weeks. 72.4% were treated according to the SmPC. The most frequent reason for lack of adherence to the SmPC was the addition of RBV (84% of prescriptions were non-concordant), followed by not adding RBV when it was recommended (6.9%), prolonged treatment duration (4.5%) and shortened treatment duration (2.5%). SVR12 in patients treated according to SmPC was 96.1%, while in patients with nonconcordant prescriptions was 96.7% (p = 0.44). In patients with shortened treatment duration, SVR12 was significantly lower than in the rest of patients (82.6% vs. 97%, p < 0.05). Conclusions: 72.4% of patients received treatment according to the SmPC. Themajority of deviations were due to RBV use. Therewere no statistically significant differences in SVR between patients treated according to the SmPC and those receiving non-concordant prescriptions. However, there was an impact in SVR for patients who were treated for less time than recommended.